Vitiligo road map

Dermatologic Therapy

Volumn 25, Issue SUPPL.1, 2012, Pages

  Lee, Brian W ^a   Schwartz, Robert A ^a   Hercogová, Jana ^b   Valle, Yan ^c   Lotti, Torello M ^d  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^c Vitiligo Research Foundation   (United States)

^d Department of Dermatological Sciences and Office of the Vice Chancellor University of Rome Guglielmo Marconi ^*  (Italy)

Author keywords

Biomarkers; Melanocyte; Melanogenesis; Pigmentation; Vitiligo

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; COLECALCIFEROL; CYTOKINE; ENDOTHELIN 1; NITRIC OXIDE; SCATTER FACTOR; SEMAPHORIN; SEMAPHORIN 7A; STEM CELL FACTOR; UNCLASSIFIED DRUG; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL VIABILITY; DENDRITE; HUMAN; INTRACELLULAR SIGNALING; MELANOCYTE; MELANOGENESIS; MICROENVIRONMENT; OXIDATIVE STRESS; PHOTOCHEMOTHERAPY; VITILIGO; ANIMAL; DOG; IMMUNOLOGY; LOW LEVEL LASER THERAPY; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHOTOTHERAPY; PHYSIOLOGY; PIGMENTATION; SKIN TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; DERMATOLOGIC AGENTS; DOGS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LASER THERAPY; MELANOCYTES; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PIGMENTATION; SKIN TRANSPLANTATION; TREATMENT OUTCOME; VITILIGO;

EID: 84875884899     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12006     Document Type: Article

References (147)

1. Maddodi N, Jayanthy A, Setaluri V. Shining light on skin pigmentation: the darker and the brighter side of effects of UV radiation. Photochem Photobiol 2012: 88: 1075-1082.
2. Ito S, Wakamatsu K. Quantitative analysis of eumelanin and pheomelanin in humans, mice, and other animals: a comparative review. Pigment Cell Res 2003: 16 (5): 523-531.
3. Hearing VJ. Biogenesis of pigment granules: a sensitive way to regulate melanocyte function. J Dermatol Sci 2005: 37 (1): 3-14.
4. Lee KY, Jeon SY,Hong JW, et al. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-alpha-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol 2012: in press.
5. Imokawa G, Yada Y, Miyagishi M. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem 1992: 267 (34): 24675-24680.
6. Sakurai T, Yanagisawa M, Takuwat Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990: 348 (6303): 732-735.
7. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004: 84 (4): 1155-1228.
8. Sato-Jin K, Nishimura EK, Akasaka E, et al. Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders. FASEB J 2008: 22 (4): 1155-1168.
9. Imokawa G, Yada Y, Kimura M. Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes. Biochem J 1996: 314 (Pt 1): 305-312.
10. Kadekaro AL, Kavanagh R, Kanto H, et al. Alphamelanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res 2005: 65 (10): 4292-4299.
11. Murase D, Hachiya A, Amano Y, et al. The essential role of p53 in hyperpigmentation of the skin via regulation of paracrine melanogenic cytokine receptor signaling. J Biol Chem 2009: 284 (7): 4343-4353.
12. Ma HJ, Zhu WY, Wang DG, Yue XZ, Li CR. Endothelin-1 combined with extracellular matrix proteins promotes the adhesion and chemotaxis of amelanotic melanocytes from human hair follicles in vitro. Cell Biol Int 2006: 30 (12): 999-1006.
13. Hachiya A, Kobayashi A, Ohuchi A, Takema Y, Imokawa G. The paracrine role of stem cell factor/c-kit signaling in the activation of human melanocytes in ultraviolet-B-induced pigmentation. J Invest Dermatol 2001: 116 (4): 578-586.
14. Imokawa G, Yada Y, Morisaki N, Kimura M. Biological characterization of human fibroblast-derived mitogenic factors for human melanocytes. Biochem J 1998: 330 (Pt 3): 1235-1239.
15. Imokawa G. Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigment Cell Res 2004: 17 (2): 96-110.
16. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999: 31 (10): 1053-1074.
17. Steel K, Davidson DR, Jackson I. TRP-2/DT, a new early melanoblast marker, shows that steel growth factor (c-kit ligand) is a survival factor. Development 1992: 115 (4): 1111-1119.
18. Rodewald HR, Kretzschmar K, Swat W, Takeda S. Intrathymically expressed c-kit ligand (stem cell factor) is a major factor driving expansion of very immature thymocytes in vivo. Immunity 1995: 3 (3): 313-319.
19. Motro B,Wojtowicz JM, Bernstein A, Van Der Kooy D. Steel mutant mice are deficient in hippocampal learning but not long-term potentiation. Proc Natl Acad Sci 1996: 93 (5): 1808.
20. Huizinga JD, Thuneberg L, Kluppel M, et al. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995: 373 (6512): 347-349.
21. Thomas I, Kihiczak GG, Fox MD, Janniger CK, Schwartz RA. Piebaldism: an update. Int J Dermatol 2004: 43 (10): 716-719.
22. Halaban R, Langdon R, Birchall N, et al. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol 1988: 107 (4): 1611-1619.
23. Halaban R, Tyrrell L, Longley J, Yarden Y, Rubin J. Pigmentation and proliferation of human melanocytes and the effects of melanocyte-stimulating hormone and ultraviolet B light. Ann N Y Acad Sci 1993: 680: 290-301.
24. Swope VB, Medrano EE, Smalara D, Abdel-Malek ZA. Long-term proliferation of human melanocytes is supported by the physiologic mitogens alpha-melanotropin, endothelin-1, and basic fibroblast growth factor. Exp Cell Res 1995: 217 (2): 453-459.
25. Matsumoto K, Tajima H, Nakamura T. Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth. Biochem Biophys Res Commun 1991: 176 (1): 45-51.
26. Halaban R, Rubin JS, Funasaka Y, et al.Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 1992: 7 (11): 2195-2206.
27. Liu Y. Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am J Physiol Renal Physiol 1999: 277 (4): F624-F633.
28. Bohm M, Moellmann G, Cheng E, et al. Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 1995: 6 (3): 291-302.
29. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995: 81 (3): 323-330.
30. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 1997: 94 (2): 701-706.
31. Botchkarev VA, Yaar M, Peters EMJ, et al. Neurotrophins in skin biology and pathology. J Invest Dermatol 2006: 126 (8): 1719-1727.
32. Bothwell M. Neurotrophin function in skin. J Investig Dermatol Symp Proc 1997: 2 (1): 27-30.
33. Roux PP, Barker PA. Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 2002: 67 (3): 203-233.
34. Choi W, Wolber R, Gerwat W, et al. The fibroblast-derived paracrine factor neuregulin-1 has a novel role in regulating the constitutive color and melanocyte function in human skin. J Cell Sci 2010: 123 (18): 3102-3111.
35. Esper RM, Pankonin MS, Loeb JA. Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. Brain Res Rev 2006: 51 (2): 161-175.
36. Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991: 96 (2): 180-185.
37. Hirobe T, Ootaka H. Interleukin-1alpha stimulates the differentiation of melanocytes but inhibits the proliferation of melanoblasts from neonatal mouse epidermis. Zoolog Sci 2007: 24 (10): 959-970.
38. Imokawa G, Yada Y, Kimura M, Morisaki N. Granulocyte/ macrophage colony-stimulating factor is an intrinsic keratinocyte-derived growth factor for human melanocytes in UVA-induced melanosis. Biochem J 1996: 313 (Pt 2): 625-631.
39. Abdel-Malek ZA, Swope VB. Epidermal melanocytes: regulation of their survival, proliferation, and function in human skin. In: Bosserhoff A, ed. Melanoma Development. New York, NY: SpringerWein New York, 2011: 7-33.
40. Suzuki I, Cone R, ImS, Nordlund J, Abdel-Malek Z. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 1996: 137 (5): 1627-1633.
41. Im S, Moro O, Peng F, et al. Activation of the cyclic AMP pathway by a-melanotropin mediates the response of human melanocytes to ultraviolet B radiation. Cancer Res 1998: 58 (1): 47.
42. Hunt G, Todd C, Cresswell JE, Thody AJ. Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha- MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J Cell Sci 1994: 107 (Pt 1): 205-211.
43. Slominski A,Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 2000: 80 (3): 979-1020.
44. Kauser S, Schallreuter KU, Thody AJ, Gummer C, Tobin DJ. Regulation of human epidermal melanocyte biology by [beta]-endorphin. J Invest Dermatol 2003: 120 (6): 1073-1080.
45. Graham A, Wakamatsu K, Hunt G, Ito S, Thody AJ. Agouti protein inhibits the production of eumelanin and phaeomelanin in the presence and absence of a-melanocyte stimulating hormone. Pigment Cell Res 1997: 10 (5): 298-303.
46. Swope VB, Jameson JA, McFarland KL, et al. Defining MC1R regulation in human melanocytes by its agonist a-melanocortin and antagonists agouti signaling protein and b-defensin 3. J Invest Dermatol 2012: 132: 2255-2562.
47. Abdel-Malek Z, Suzuki I, Tada A, Im S, Akcali C. The melanocortin-1 receptor and human pigmentation. Ann N Y Acad Sci 1999: 885: 117-133.
48. Steinhoff M, Brzoska T, Luger TA. Keratinocytes in epidermal immune responses. Curr Opin Allergy Clin Immunol 2001: 1 (5): 469.
49. Park HY, Wu C, Yaar M, et al. Role of BMP-4 and its signaling pathways in cultured human melanocytes. Int J Cell Biol 2009: 2009: 750482.
50. Yaar M, Wu C, Park HY, et al. Bone morphogenetic protein-4, a novel modulator of melanogenesis. J Biol Chem 2006: 281 (35): 25307-25314.
51. Sharov AA, Fessing M, Atoyan R, et al. Bone morphogenetic protein (BMP) signaling controls hair pigmentation by means of cross-talk with the melanocortin receptor-1 pathway. Proc Natl Acad Sci U S A 2005: 102 (1): 93.
52. Scott GA, McClelland LA, Fricke AF. Semaphorin 7a promotes spreading and dendricity in human melanocytes through b1-integrins. J Invest Dermatol 2007: 128 (1): 151-161.
53. Soong J, Chen Y, Shustef EM, Scott GA. Sema4D, the ligand for Plexin B1, suppresses c-Met activation and migration and promotes melanocyte survival and growth. J Invest Dermatol 2012: 132 (4): 1230-1238.
54. Morelli JG, Yohn JJ, Lyons MB,Murphy RC, Norris DA. Leukotrienes C4 and D4 as potent mitogens for cultured human neonatal melanocytes. J Invest Dermatol 1989: 93 (6): 719-722.
55. Morelli JG, Kincannon J, Yohn JJ, et al. Leukotriene C4 and TGF-alpha are stimulators of human melanocyte migration in vitro. J Invest Dermatol 1992: 98 (3): 290-295.
56. Scott G, Leopardi S, Printup S, et al. Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2a on melanocyte dendricity. J InvestDermatol 2004: 122 (5): 1214-1224.
57. Scott G, Fricke A, Fender A, McClelland L, Jacobs S. Prostaglandin E2 regulates melanocyte dendrite formation through activation of PKC [zeta]. Exp Cell Res 2007: 313 (18): 3840-3850.
58. Starner RJ,McClelland L, Abdel-Malek Z, Fricke A, Scott G. PGE2 is a UVR-inducible autocrine factor for human melanocytes that stimulates tyrosinase activation. Exp Dermatol 2010: 19 (7): 682-684.
59. Jackson M, Frame F, Weller R, McKenzie RC. Expression of nitric oxide synthase III (eNOS) mRNA by human skin cells: melanocytes but not keratinocytes express eNOS mRNA. Arch Dermatol Res 1998: 290 (6): 350-352.
60. Stallmeyer B, Kämpfer H, Kolb N, Pfeilschifter J, Frank S. The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely impairs wound reepithelialization. J Invest Dermatol 1999: 113 (6): 1090-1098.
61. Wang R, Ghahary A, Shen YJ, Scott PG, Tredget EE. Human dermal fibroblasts produce nitric oxide and express both constitutive and inducible nitric oxide synthase isoforms. J Invest Dermatol 1996: 106 (3): 419-427.
62. Dong Y, Cao J, Wang H, et al. Nitric oxide enhances the sensitivity of alpaca melanocytes to respond to a-melanocyte-stimulating hormone by up-regulating melanocortin-1 receptor. Biochem Biophys Res Commun 2010: 396 (4): 849-853.
63. Ivanova K, Lambers B, Van DenWijngaard R, et al. Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP. In Vitro Cell Dev Biol Anim 2008: 44 (8): 385-395.
64. Ivanova K, Le Poole IC, Gerzer R, Westerhof W, Das PK. Effects of nitric oxide on the adhesion of human melanocytes to extracellular matrix components. J Pathol 1997: 183 (4): 469-476.
65. Schwartz RA, Fernández G, Kotulska K, Józwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007: 57 (2): 189-202.
66. Sun X, Xu A,Wei X, et al. Genetic epidemiology of vitiligo: a study of 815 probands and their families fromsouth China. Int J Dermatol 2006: 45 (10): 1176-1181.
67. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003: 16 (3): 208-214.
68. Prignano F, Pescitelli L, Ricceri F, Lotti T. The importance of genetical link in immuno-mediated dermatoses: psoriasis and vitiligo. Int J Dermatol 2008: 47 (10): 1060-1062.
69. Abu Tahir M, Pramod K, Ansari SH, Ali J. Current remedies for vitiligo. Autoimmun Rev 2010: 9 (7): 516-520.
70. Spritz RA. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid 2010: 20 (7): 745-754.
71. Jin Y, Ferrara T, Gowan K, et al. Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation. J Invest Dermatol 2012: 132 (6): 1730-1733.
72. Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo. J Dermatol Sci 2005: 39 (3): 137-146.
73. Liu JB, Li M, Chen H, et al. Association of vitiligo with HLAA2: a meta-analysis. J Eur Acad DermatolVenereol 2007: 21 (2): 205-213.
74. Cui J, Arita Y, Bystryn JC. Characterization of vitiligo antigens. Pigment Cell Res 1995: 8 (1): 53-59.
75. Ruiz-Argüelles A, Brito GJ, Reyes-Izquierdo P, Pérez- Romano B, Sánchez-Sosa S. Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun 2007: 29 (4): 281-286.
76. Birlea SA, Laberge GS, Procopciuc LM, Fain PR, Spritz RA. CTLA4 and generalized vitiligo: two genetic association studies and a meta-analysis of published data. Pigment Cell Melanoma Res 2009: 22 (2): 230-234.
77. Kim JY, Shin JY, Kim M, Hann SK, Oh SH. Expression of cytosolic NADP(+)-dependent isocitrate dehydrogenase in melanocytes and its role as an antioxidant. J Dermatol Sci 2012: 65 (2): 118-125.
78. Shi F, Kong BW, Song JJ, et al. Understanding mechanisms of vitiligo development in Smyth line of chickens by transcriptomic microarray analysis of evolving autoimmune lesions. BMC Immunol 2012: 13: 18.
79. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996: 148 (4): 1219-1228.
80. Palermo B, Campanelli R, Garbelli S, et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001: 117 (2): 326-332.
81. Zhou L, Li K, Shi YL, et al. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells. Pigment Cell Melanoma Res 2012: 25: 602-611.
82. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br JDermatol 1994: 131 (2): 160-165.
83. Schallreuter KU, Wood JM, Ziegler I, et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1994: 1226 (2): 181-192.
84. Park ES, Kim SY, Na JI, et al. Glutathione prevented dopamine-induced apoptosis of melanocytes and its signaling. J Dermatol Sci 2007: 47 (2): 141-149.
85. Morrone A, Picardo M, de Luca C, et al. Catecholamines and vitiligo. Pigment Cell Res 1992: 5 (2): 65-69.
86. Cucchi ML, Frattini P, Santagostino G, Preda S, Orecchia G. Catecholamines increase in the urine of non-segmental vitiligo especially during its active phase. Pigment Cell Res 2003: 16 (2): 111-116.
87. Iyengar B. Modulation of melanocytic activity by acetylcholine. Cells Tissues Organs 1989: 136 (2): 139-141.
88. Schallreuter K, Wood J, Pittelkow M, et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res 1996: 288 (1): 14-18.
89. Land EJ, Ramsden CA, Riley PA. Toxicological aspects of melanin and melanogenesis. In: Nordlund JJ, Boissy RE, Hearing VJ, et al., eds. The Pigmentary System. Oxford, UK: Blackwell Publishing Ltd, 2007: 354-394.
90. Kumar R, Parsad D. Melanocytorrhagy and apoptosis in vitiligo: connecting jigsaw pieces. Indian J Dermatol Venereol Leprol 2012: 78 (1): 19.
91. Hann SK, Chun WH. Autocytotoxic hypothesis for the destruction of melanocytes as the cause of vitiligo. In: Nordlund, J., ed. Vitiligo: a monograph on the basic and clinical science. Oxford, UK: Blackwell Science Ltd, 2008: 137-141.
92. Schallreuter KU, Buttner G, Pittelkow MR, et al. Cytotoxicity of 6-biopterin to human melanocytes. Biochem Biophys Res Commun 1994: 204 (1): 43-48.
93. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991: 97 (6): 1081-1085.
94. Beazley WD, Gaze D, Panske A, Panzig E, Schallreuter KU. Serum selenium levels and blood glutathione peroxidase activities in vitiligo. Br J Dermatol 1999: 141 (2): 301-303.
95. Schallreuter KU, Pittelkow MP. Defective calcium uptake in keratinocyte cell cultures from vitiliginous skin. Arch Dermatol Res 1988: 280 (3): 137-139.
96. Toosi S, Orlow SJ,Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol 2012: 132: 2601-2609.
97. Nishimura EK, Jordan SA, Oshima H, et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 2002: 416 (6883): 854-860.
98. Kumar R, Parsad D, Kanwar A. Role of apoptosis and melanocytorrhagy: a comparative study of melanocyte adhesion in stable and unstable vitiligo. Br JDermatol 2011: 164 (1): 187-191.
99. Cario-André M, Pain C, Gauthier Y, Taieb A. The melanocytorrhagic hypothesis of vitiligo tested on pigmented, stressed, reconstructed epidermis. Pigment Cell Res 2007: 20 (5): 385-393.
100. Kumar R, Parsad D, Kaul D, Kanwar A. Liver X receptor expression in human melanocytes, does it have a role in the pathogenesis of vitiligo? Exp Dermatol 2010: 19 (1): 62-64.
101. Kitamura R, Tsukamoto K, Harada K, et al. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF-M. J Pathol 2004: 202 (4): 463-475.
102. Lee A-Y, KimN-H, ChoiW-I, Youm Y-H. Less keratinocytederived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo. J Invest Dermatol 2005: 124 (5): 976-983.
103. Hann SK, Kim HI, Im S, et al. The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients. J Dermatol Sci 1993: 6 (3): 201-205.
104. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al. Local immune response in skin of generalized vitiligo patients.Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000: 80 (8): 1299-1309.
105. Rezaei N, Gavalas NG,Weetman AP, Kemp EH. Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol 2007: 21 (7): 865-876.
106. Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview: part II: treatment options and approach to treatment. J Am Acad Dermatol 2011: 65 (3): 493-514.
107. Mahmoud BH, Hexsel CL, Hamzavi IH. An update on new and emerging options for the treatment of vitiligo. Skin Therapy Lett 2008: 13 (2): 1-6.
108. Lan CC, Chen GS, Chiou MH, et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br JDermatol 2005: 153 (3): 498-505.
109. Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 2008: 9 (4): 345-359.
110. Ameen M, Exarchou V, Chu A. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001: 145 (3): 476-479.
111. Lotti T, Prignano F, Buggiani G. New and experimental treatments of vitiligo and other hypomelanoses. Dermatol Clin 2007: 25 (3): 393-400.
112. Ozawa M, Ferenczi K, Kikuchi T, et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999: 189 (4): 711-718.
113. Ponsonby AL, Lucas RM, van der Mei IAF. UVR, vitamin D and three autoimmune diseases - multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem Photobiol 2005: 81 (6): 1267-1275.
114. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001: 182 (1): 18-32.
115. Soontrapa K, Honda T, Sakata D, et al. Prostaglandin E2-prostoglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc Natl Acad Sci 2011: 108 (16): 6668-6673.
116. Wu CS, Yu CL, Wu CS, Lan CC, Yu HS. Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol 2004: 13 (12): 755-763.
117. Prignano F, Ricceri F, Bianchi B, et al. Dendritic cells: ultrastructural and immunophenotypical changes upon nb-UVB in vitiligo skin. Arch Dermatol Res 2011: 303 (4): 231-238.
118. Lotti T, Buggiani G, Troiano M, et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects.Dermatol Ther 2008: 21 (Suppl. 1): S20-S26.
119. Novák Z, Bónis B, Baltás E, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B Biol 2002: 67 (1): 32-38.
120. Pacifico A, Leone G. Photo(chemo)therapy for vitiligo. Photodermatol Photoimmunol Photomed 2011: 27 (5): 261-277.
121. Anbar TS, El-Sawy AE, Attia SK, et al. Effect of PUVA therapy on melanocytes and keratinocytes in nonsegmental vitiligo: histopathological, immunohistochemical and ultrastructural study. Photodermatol Photoimmunol Photomed 2012: 28 (1): 17-25.
122. Wu CS, Lan CCE, Wang LF, et al. Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 2007: 156 (1): 122-129.
123. Kao C-H, Yu H-S. Comparison of the effects of 8-methoxypsoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro. J Invest Dermatol 1992: 98 (5): 734-740.
124. Kao CH, Yu HS. Depletion and repopulation of Langerhans cells in nonsegmental type vitiligo. J Dermatol 1990: 17 (5): 287-296.
125. Falabella R. Surgical approaches for stable vitiligo. Dermatol Surg 2005: 31 (10): 1277-1284.
126. Patel NS, Paghdal KV, Cohen GF. Advanced treatment modalities for vitiligo. Dermatol Surg 2012: 38 (3): 381-391.
127. Czajkowski R. BRAF, HRAS, KRAS, NRAS and CDKN2A genes analysis in cultured melanocytes used for vitiligo treatment. Int J Dermatol 2011: 50 (2): 180-183.
128. Inamadar AC, Palit A. Acrodermatitis enteropathica with depigmented skin lesions simulating vitiligo. Pediatr Dermatol 2007: 24 (6): 668-669.
129. Helmy M, Gayyar E, Hawas S, Eissa A. Role of oxidative stress in the pathogenesis of vitiligo. J Pan-Arab League Dermatol 2004: 15: 97-105.
130. Hernick M, Fierke CA. Zinc hydrolases: the mechanisms of zinc-dependent deacetylases. Arch Biochem Biophys 2005: 433 (1): 71-84.
131. Schallreuter KU, Moore J, Behrens-Williams S, Panske A, Harari M. Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol 2002: 41 (8): 482-487.
132. Sanclemente G, Garcia JJ, Zuleta JJ, et al. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol 2008: 22 (11): 1359-1364.
133. Khemis A, Ortonne J. Etude comparative d'un extrait vegetal possedant une activité superoxide dismutase (VITIX®) plus phototherapie UVB selective versus son excipient plus phototherapie selective dans le traitement du vitiligo vulgaire. Nouv Dermatol 2004: 23: 7-11.
134. Dell'Anna ML, Mastrofrancesco A, Sala R, et al. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol 2007: 32 (6): 631-636.
135. Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrowband UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2007: 21 (7): 942-950.
136. Becatti M, Prignano F, Fiorillo C, et al. The involvement of Smac/DIABLO, p53, NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin. Antioxid Redox Signal 2010: 13 (9): 1309-1321.
137. Bolognia JL, Lapia K, Somma S. Depigmentation therapy. Dermatol Ther 2001: 14 (1): 29-34.
138. Rao J, Fitzpatrick RE. Use of the Q-switched 755-nm alexandrite Laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg 2004: 30 (7): 1043-1045.
139. Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert J. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005: 210 (4): 279-285.
140. Tedeschi A, Dall'Oglio F, Micali G, Schwartz RA, Janniger CK. Corrective camouflage in pediatric dermatology. Cutis 2007: 79 (2): 110-112.
141. Tanioka M,Miyachi Y. Camouflaging vitiligo of the fingers. Arch Dermatol 2008: 144 (6): 809.
142. Mahajan BB, Garg G, Gupta RR. Evaluation of cosmetic tattooing in localised stable vitiligo. J Dermatol 2002: 29 (11): 726-730.
143. Nishimura EK, Suzuki M, Igras V, et al. Key roles for transforming growth factor [beta] in melanocyte stem cell maintenance. Cell Stem Cell 2010: 6 (2): 130-140.
144. Cui J, Shen LY, Wang G. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991: 97 (3): 410-416.
145. Falabella R. Vitiligo and the melanocyte reservoir. Indian J Dermatol 2009: 54 (4): 313.
146. Al-Shobaili HA. Updates on the genetic characterization of vitiligo. Int J Health Sci 2012: 5 (2): 167-179.
147. Harris JE, Harris TH, Weninger W, et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol 2012: 132: 1869-1876.